Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Titan Pharmaceuticals is a biotechnology business based in the US. Titan Pharmaceuticals shares (TTNP) are listed on the NASDAQ and all prices are listed in US Dollars. Titan Pharmaceuticals employs 11 staff and has a trailing 12-month revenue of around $571,000.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $1.00 |
|---|---|
| 52-week range | $0.35 - $1.59 |
| 50-day moving average | $0.90 |
| 200-day moving average | $0.96 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.87 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1 from 2023-02-06
| 1 week (2023-02-01) | 1.01% |
|---|---|
| 1 month (2023-01-06) | 11.11% |
| 3 months (2022-11-08) | 5.40% |
| 6 months (2022-08-08) | -26.47% |
| 1 year (2022-02-04) | -17.36% |
|---|---|
| 2 years (2021-02-08) | -74.29% |
| 3 years (2020-02-07) | 7.23 |
| 5 years (2018-02-08) | -99.49% |
| Revenue TTM | $571,000 |
|---|---|
| Gross profit TTM | $-4,365,000 |
| Return on assets TTM | -79.44% |
| Return on equity TTM | -184.32% |
| Profit margin | 0% |
| Book value | $0.24 |
| Market capitalisation | $14.5 million |
TTM: trailing 12 months
We're not expecting Titan Pharmaceuticals to pay a dividend over the next 12 months.
Titan Pharmaceuticals's shares were split on a 1:30 basis on 30 November 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Titan Pharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Titan Pharmaceuticals shares which in turn could have impacted Titan Pharmaceuticals's share price.
Over the last 12 months, Titan Pharmaceuticals's shares have ranged in value from as little as $0.3496 up to $1.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Titan Pharmaceuticals's is 1.0356. This would suggest that Titan Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Titan Pharmaceuticals, Inc. , a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
